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Abstract
This epileptic disorder has become a classic topic for neuropediatricians and the interest is documented by the
large number of publications on this subject.
The relative frequency among the epileptic syndromes is an another reason why not only neuropediatricians but
also general pediatricians must be fully informed about diagnostic, clinical, imaging and genetic aspects.
Early diagnosis is of paramount importance in order to obtain even complete results in patients with so called idio-
pathic situations. A number of problems are still to be solved. There is no agreement on the type and the sche-
dule of treatment. A common denominator about this problem is not jet available even if some advances in this
regard have been accomplished. Of paramount importance is an accurate clinical and laboratory examination as a
prerequisite regarding prognosis and results of therapy in every single case.
However, even if more than 170 years have elapsed since the first communication of dr. West on the peculiar syn-
drome that his child was suffering of, the interest of scientists on this subject has now been enriched and
rewarded.
Introduction
This epileptic disorder of infancy or early childhood was
first described by Dr. William James West in 1841 in his
son [1].
It is characterized by the triad of infantile spasms,
hypsarrhythmia, and retardation. The EEG pattern (hyp-
sarrhythmia) was illustrated by Gibbs [2]. The descrip-
tion of Dr. West is exhaustive: the spasms begun when
his son was 4 months old and are described accurately.
“The bowing and relaxing of the head and trunk would
be repeated alternatively at intervals of few seconds and
from ten to twenty or more times at each attack that
would continue not more than two or three minutes ...
sometimes two, three or more attacks in the day. The
child appeared frightened and screamed.... he neither
possessed the intellectual vivacity or the power of hold-
ing himself upright or using his limbs, and his head falls
without support.” Dr. West assumed that spasms were
caused by an irritation of the nervous system, perhaps
c a u s e db yt e e t h i n g .T h eu s e dr e m e d i e sw e r en oa v a i l .
The patient died in an institution at the age of 20 years
[3].
Infantile spasms (IS) is “one of the catastrophic child-
hood epilepsies” due to the difficulty of controlling sei-
zures and the association with mental retardation. Early
diagnosis with a careful diagnostic evaluation and proper
therapy can obtain a normal development or a much
improved situation in some cases [4].
This syndrome is also referred in literature as massive
spasms, Salaam tics, infantile myoclonic seizures or
Blitz-Nick-Salaam Krämpfe. It has been classified in the
category of generalized seizures with specific EEG char-
acteristics. Focal seizures as well as focal lesions can
also be present [5].
IS have been classified as idiopathic when another
neurologic disorder is not identified, cryptogenic when a
possible etiology is suspected but not identified and
symptomatic when a definite etiology can be demon-
strated. From this point of view it is important to distin-
guish if patients were neurologically normal before the
o n s e to fs y m p t o m sf r o mt h o s ei nw h i c ht h i si sn o tt h e
case. It must be noted that the terms idiopathic or cryp-
togenic are used by some authors interchangeably when
symptoms developed in a previously normal child.
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The incidence of IS has been estimated to be between
1:4000 to 1:6000 live births [6] and has not substantially
changed. In the report of Riikonen the overall incidence
of IS was 30,7/100.000 live births [7]. Etiologic classifica-
tion was symptomatic in 68% cryptogenic in 24% and
idiopathic in 8% of children. There can be however a
marked variability in annual and five years incidence
rates [8].
Evolution
S p a s m su s u a l l ya p p e a ri nt h ef i r s t2y e a r so fl i f ew i t ha
peak between 4 and 6 months and sometimes continue
until adolescence. In cases that do not respond to ther-
apy they are substituted by different types of seizures.
The disorder can evolve in a Lennox-Gastaut syndrome:
this possibility can favour the hypothesis that this hap-
pens because the syndromes manifestation are age
related [9].
Relationship with Other Epileptic Syndromes
Early myoclonic encephalopathy (EME) and Ohtahara
syndrome are currently listed as two separate syndromes
in the classification of epilepsy.
Patients with Ohtahara syndrome have prevalently
tonic seizure that frequently evolve in infantile spasms:
the prognosis is often worst than in patients with EME.
However there is an overlap in the etiologies. Tonic
seizures are considered a manifestation of brainstem
dysfunction and is possible that they are more promi-
nent in the Ohtahara syndrome [10].
Etiology
A number of pathologies has been documented as asso-
ciated factor for IS. These are indicated in Appendix 1.
Metabolic disorders have been implicated. To list only
the most recent: d-glyceric aciduria [11], Menkes disease
[12], mitochondrial diseases [13,14], pyruvate dehydro-
genase E1 alpha subunit deficiency [15], phenylketonuria
[16], hypoglycaemia [17], Alexander disease [18], CDG
deficient syndrome, biotinidase deficiency [19], Leigh
syndrome [20], methylmalonic aciduria [21], propionic
acidemia [22], vitamin B12 deficiency [23], d-bifunc-
tional protein deficiency [24], SCAD deficiency [25],
Hurler syndrome [26].
Malformations such as microcephaly, lissencephaly
and tetralogy of Fallot [27] and malformation of cortical
development (MCDS) can cause IS. In this last possibi-
lity the MRI can be normal but functional neuroimaging
can be indicative [28]. In these cases the hypsarrhythmia
can be asymmetric. Familiar periventricular heterotopia
with mutation in filamin A (FLNA) gene, an X-linked
dominant disorder, can cause West syndrome in males
[29,30]. Tuberous sclerosis complex (TSC) is a frequent
cause of symptomatic IS [31]. Gyration abnormalities
[32] polimicrogiria [33] and [34] are also associated.
Dysmorphogenetic sindromes are also described
together with IS. Aicardi syndrome is an X-linked domi-
nant condition characterized by IS, agenesis of corpus
callosum and chorioretinal lacunae. It occurs only in
individuals with two X chromosomes and is not familial.
The brain malformation is complex with cortical migra-
tion abnormalities heterotopias microgyria or pachigiria
and subependimal cortical heterotopias, often cystic for-
mations and sometimes choroids plexus papillomas. The
eye anomalies, often feature a coloboma in addition to
the lacunae, are common. Since it has been reported in
two boys with XXY, complement, an X-linked gene
lethal in early pregnancy for males is supposed [35,36].
Kabuki syndrome with multiple malformation and pecu-
l i a rf a c ew h i c hr e s e m b l e saK a b u k ia c t o r[ 3 7 ] .N o r r i e
disease, a rare X-linked recessive disorder with congeni-
tal blindness [38], Schinzel-Giedion syndrome character-
ized by a midfacial retraction, kidney and urinary
malformations, multiple skeletal abnormalities and neu-
rodegeneration [39], Sotos syndrome (cerebral gigant-
ism) [40] and Williams syndrome with craniosynostosis
[41] have also been found to be associated.
Another possible association is PEHO syndrome a
progressive encephalopathy with edema, hypsarrhytmia
and optic atrophy. It is a rare neurodegenerative disor-
der: most patients are of Finnish descent. There is
marked cerebellar atrophy and infantile spasms [42,43].
IS can also be associated in DEND syndrome, character-
ized by developmental delay, epilepsy and neonatal dia-
betes [44].
IS can have an infectious origin which can be sup-
posed or demonstrated, in particular with exanthema
subitum. Cytomegalovirus has been also implicated
[45,46]. These cases can undergo spontaneous
remission.
Cerebral tuberculomas have also been reported
[47,48]. These observations together with observed
immunologic abnormalities [49] and an increase of
interleukin -6 levels in the cerebrospinal fluid [50] are
in favour of an immune pathogenesis.
The possible relationship between vaccinations and
West syndrome hypotesized for long time, has been
recently ruled out [51].
Neoplasms such as leptomeningeal angiomatosis [52]
and basal ganglia glioma have been implicated [53].
Destructive lesions (encephalomalacia) Sturge-Weber
syndrome and neoplasm can cause IS but the most
common neuropathologic finding is cortical dysplasia
(CT). This last finding underscores the similarity of IS
in tuberous sclerosis [54].
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and the onset of ISS which often cannot be determined.
The interval between brain injury and the onset of
infantile spasms ranges from 6 weeks to 2 months and a
similar interval occurs in children with perinatal cerebral
infarction. This time interval is against the close tem-
poral association between immunization and onset of IS
[55].
Genetic errors such as Down’s syndrome [56], trisomy
4 p [57], cri du chat syndrome [58], terminal 1p36 dele-
tion [59] can cause IS. Changes at molecular level such
as sodium channel mutations [60] have now been found.
In the large majority of cases West syndrome is not
familiar but sometimes can be transmitted as X-linked
disorder. In this case the mutation is related to ARX
homeobox gene which is a homolog of the drosophila
gene Aristaless (OMIM 300382) located on Xp 22.13. It
contains 5 exons and encodes a protein which may reg-
ulate brain development [61] The most common muta-
tion in ARX is a 24 bp duplication in exon 2 resulting
in an expansion of the polyalanine tract. The Aristaless-
paired homeobox, is a highly conserved octapeptide
expressed in the brain as well as in other tissues. Many
disease phenotypes have been associated with this gene.
Among them are severe dystonia and quadriparesis
without neuro-imaging findings of perinatal injury but
small areas of abnormally increased signal intensity in
the putamina, spasticity, intellectual disability and myo-
clonic epilepsy. The ARX mutations possibly causes
intranuclear aggregation of mutant ARX protein and
cell death in neurons [62-64]. Mutation in another gene
can cause severe developmental disorder with infantile
spasms.
Since ARX is also associated to X-linked mental retar-
dation (MR) and other epileptic syndromes, this finding
suggest the existence of a relationship between MR and
epilepsy at molecular level [65].
Mutations in ARX gene have been found also in aut-
ism and dystonia but also in sporadic cryptogenetic
infantile spasms in X-linked lissencephaly with abnormal
genitalia (XLAG), agenesis of corpus callosum and mid-
brain malformations (ACC) [66-68].
In two female patients with de novo balanced auto-
some translocations, the serine-threonine kinase 9
(STK9) gene was disrupted. This gene maps distal to
ARX in Xp 22.3 region. The phenotype of these two sis-
ters was identical consisting in early onset IS, profound
global developmental arrest, hypsarrhythmia ad severe
mental retardation. This suggest that lack of STK9 func-
tional protein causes severe X linked IS (ISSX) and
moreover indicate that STK9 is a second locus for this
disorder [69]. More recently this gene has been demon-
strated to be the same of CDKL5 and therefore it is
related to this encephalopathy. Polyalanine tract
expansion (33 bp duplication) has been found also in a
patient with Ohtahara syndrome [70].
Pathogenesis
It was been suggested that IS may result from a particu-
lar temporal desynchronization of two or more central
nervous system developmental processes resulting in a
specific disturbance of brain function, postulated to be
dependent on an unbalanced maturation pattern. This
disturbed function could result from multiple causative
factors and therefore be associated with a variety of dif-
ferent structural and/or biochemical abnormalities com-
patible with the observed multiplicity of etiological
associations [71]. Since IS are often associated with cor-
tical abnormalities Chugani proposes an hypothesis
which considers the involvement of a cortical and sub-
cortical mechanism [72].
As already mentioned the recent consensus for pertus-
sis vaccination (a debated issue for more 50 years) is
that the risk of vaccine induced encephalopathy and/or
epilepsy, if it exist at all, is extremely low [50].
Clinical Findings
The most typical manifestations are the spasms. They
are muscular contractions lasting 1-2 seconds. They are
slower than a myoclonic jerk but more rapid of a tonic
seizure. Spasms can be synchronized in the EEG with a
fast head nods or with violent flexion of trunk, arms
and legs. Brief spasms can be easily misinterpreted by
parents or physician and, especially when consisting of
flexion of inferior limbs on the abdomen, considered as
“colics”. Spasms can be of the flexor or extension or
mixed flexor extension types of the neck, trunk, arms
and legs. When asymmetric they are and usually present
in symptomatic cases and temporally associated with
partial or generalized seizures. Autonomic symptom
such as skin flushing, sweating, pupillary dilatation or
changes in respiratory or heart rate can be present
[73,74].
Spasms often appear in cluster, their number varying
conspicuously, also during the sleep or the awakening.
Irritability or crying is frequent during or after the
spasms. In the idiopathic cases the child developmental
level at the beginning of symptoms may appear normal.
However, already after few days the parents may notice
a slower attention or irritability. In patients with an
identifiable cause different neurologic abnormalities or
retardation are present.
EEG Findings
Marked abnormalities of the EEG are usually present. In
the idiopathic cases the initial EEG, if the onset of
symptoms is very recent, can be normal or borderline.
In these cases a repeat EEG after 7-10 days is necessary.
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[75] (Fig 1).
I tc o n s i s ti nam i x e dp a t t e rn of high voltage slow
waves mixed with spikes or polyspikes. These abnormal-
ities are continuous or almost continuous. Some form of
modified hypsarrhythmia have been described with asso-
ciated focal discharges, interhemispheric asynchrony or
periodic attenuation of the discharges. The EEG equiva-
lent of the myoclonic jerks is a brief burst of spike and
w a v e so rp o l y s p i k e sa c t i v i t yd u r i n gat o n i cs e i z u r e .T h e
normal sleep pattern is absent. Sometimes sleep spindles
may be noted. They usually reappear when the result of
therapy is favourable. The hypsarrhythmic pattern is
very useful in differentiating West syndrome from
others non epileptic attacks.
Differential Diagnosis
In this regard other epileptic and nonepileptic manifes-
tations must be considered. Spasms are different from
myoclonic jerks and tonic seizures. Polygraphy is very
useful for the differentiation. Myoclonic jerks are a rapid
muscular contractions lasting less than 200 milliseconds
with an EEG correlate of a diffuse fast spikes and waves
or polyspike discharges. Tonic seizures are prolonged
muscular contractions with progressive intensity and
EEG correlate of fast spikes. As already mentioned the
EEG finding in spasms is a spike and wave discharge
with a prominence of the slow waves. For the differen-
tiation is important the type and duration of the muscu-
lar discharge. Epileptic spasms with late onset are
described: they could represent an intermediary type of
epileptic encephalopathy between West and Lennox-
Gastaut syndrome [76].
Epileptic spasms even in clusters can be present with-
out EEG findings of typical or modified hypsarrhythmia
with or without focal paroxysmal discharges on the EEG
and normal metabolic and imaging findings. It is not
clear if they must be considered a variant of West
syndrome [77]. Benign spasms are tonic contractions
while awake or asleep. The EEG is normal [78].
IS can evolve in Lennox-Gastaut syndrome. Ohtahara
syndrome (OS) can develop in IS. It is the earliest form
of age dependent epileptic encephalopathy:it is charac-
terized by frequent tonic spasms which begin in the first
months of life and a suppression burst pattern in the
EEG. The cardinal seizure type in OS is tonic seizures
occurring in cluster, either in the waking or the sleeping
state. Focal motor seizures and hemiconvulsions are pre-
sent in about half of the cases. Seizure are often intract-
able. The differentiation from the IS is useful but not so
important in that West syndrome develop from 3-6
months of age and LGS from 1-3 years of age. The
same considerations are valid for the early myoclonic
encephalopathy (EME). EME seems not to have a speci-
fic evolution with age [79].
Imaging
Imaging studies have substantially improved our under-
standing of etiology in IS. The hypoxic ischemic ence-
phalopathy is a primary cause in 30% of cases. Delayed
myelination seems to be independent of specific etiology
[80] and can be present at the onset of cryptogenic
West syndrome. Neither the seizure outcome nor devel-
opmental status are positively correlated with this find-
ing [81].
Abnormal MRI signal in the basal ganglia due to
T8993G mt DNA can indicate a mitocondrial mutation
as in three reported case of IS with hypsarrhythmia.
Vigabatrin and steroids controlled the spasms. In a fol-
low up of several years the patients were hypotonic and
had hyperlactatorrachia. Neuropathy and retinopathy
were also present [82]. In four patients with early onset
West syndrome a severe hypomyelination and reduction
in cerebral white matter has been reported. The patients
had profound psychomotor delay, impaired visual atten-
tion and acquired microcephaly and spastic tetraplegia
[83].
Neuroimaging studies have frequently demonstrated
cortical dysplastic lesions. However a cortical dysplasia
may not be evident until myelination is advanced and
the poor gray-white matter differentiation becomes visi-
ble. For these reason the dysplastic lesion can be
detected earlier using PET scanning of glucose metabo-
lism. Further study with PET tracers alpha [(11)C]
methyl-L-tryptophan and [(11)C] flumazenil as tracers
of serotonergic and gabaergic neurotransmitter systems
are useful [84]. The absence of PET abnormalities in
infants with cryptogenic IS is a good prognostic sign
regarding a favourable development or seizure outcome.
PET abnormalities can be transient [85] often associated
with hypometabolic cortical foci especially in the occipi-
tal area. When transient they are not necessary due to
Figure 1 Spontaneous sleep Eight month old male baby.
Hypsarrhythmia. Continuous diffuse irregular slow waves mixed with
multifocal spikes. Absence of normal sleep features.
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[86]. With diffusion tensor imaging it is possible to
visualize abnormalities not otherwise demonstrable.
This technique is quite recent and has not been uti-
lized in the patients considered in this review. For more
details, see “Progress in epileptic spasms and West syn-
drome. Guzzetta F, Dalla Bernardina B, Guerrini R, John
Libbey Eurotext 2007”.
Prognosis
Outcome in West syndrome varies considerably and is
correlated with etiology. In cryptogenic cases prognosis
is significantly better than in symptomatic cases. In a
s t u d yo f4 5p a t i e n t sw i t hc ryptogenic West syndrome
reported by Ducal 30 patients had a favourable outcome.
Children with normal neurological history and evalua-
tion before the onset of spasms have a much better
prognosis in comparison with children with develop-
mental retardation or abnormal neurologic status. Onset
of spasms in the first months of life is also a negative
prognostic factor since is related to the etiology. Rapid
cessation of spasms and normalization of the EEG are
favourable signs [87]. All these aspects are shared by
our experience (Fois A: Umpublished data).
A successful treatment of West syndrome is a very
important endeavour since can change completely the
social personal outcome. Opinion regarding this issue
are by no means uniform probably reflecting differences
related to a retrospective patients evaluation. In a series
of 37 patients treated for a long period with high dose
tetracosactide depot followed by oral prednisolone
slowly tapered for at least five months a normal cogni-
tive outcome was found in 100% of cryptogenic cases
treated within one month from the beginning of symp-
toms [88].
The different outcome of West syndrome depends on
the etiology [89]. A short treatment interval from the
beginning of the symptoms seem to be associated with a
favourable outcome. Reapperance of paroxysmal dis-
charges and evolution to other types of seizures may be
associated to undetected lesions [90]. Riikonen has eval-
uated the long term outcome of 214 Finnish children
with West syndrome. A third of the patients died in the
follow up 20-35 yars A third of them died before the
age of 3 years mostly for infection. Intellectual outcome
was normal or slightly impaired in a quarter of the
patients. Factors associated with good prognosis were
cryptogenic etiology, normal development before treat-
ment, short treatment lag and a good response to
ACTH [91].
Infantile spasms may reemerge as intractable epileptic
spasms. This events may be very difficult to treat [92].
The risk of a cognitive problems in children with a
cryptogenic IS increased when treatment was started
after more than three weeks of hypsarrhythmia duration
[93].
Treatment
The best practice to treat IS does not seem to have yet
be determined. There is still a lack of consensus about
the first choice treatment. Two options are at the
moment available: the first is corticotrophin or oral ster-
oids, the other is the use of vigabatrin or other antiepi-
leptic drugs. In selected resistant case a surgical option
can also be considered. An international consensus on a
therapeutic protocol and standard outcome measures
should be adopted. It has also been suggested to aban-
don the terms cryptogenic and idiopathic using instead
symptomatic and nonsymptomatic [94,95].
Sorel first reported in 1958 the beneficial effect of cor-
ticotrophin therapy [96]. On later studies modalities of
this treatment have been quite different influencing the
frequency and the intensity of the adverse events which
are mainly related to the dosage and length of treat-
ment. Synthetic derivates seem to be more frequently
associated to adverse effects. These include weight and
blood pressure changes, infections, also with opportunis-
tic organism, hyperglycemia and electrolyte abnormal-
ities, cushingoid appearance, development of new
seizure types, sleep and behaviour abnormalities and
decrease of bone density sometimes with fractures, skin
rashes with intravascular coagulation and even death. In
the referred studies doses of ACTH were however
mostly superior to 150 U/square m/day [97,98]. For this
reason a much lower dosage and shorter treatment have
recently been utilized.
Doses of 3-6 U/kg/day have been administered by Rii-
konen [99]. Lower dosage has been used in Japan and
reported to be as effective as higher doses of previous
studies [100]. From 0.2 to 1.28 IU/Kg with a total
dosage from 4 to 34.8 IU of synthetic ACTH have been
used. The severity of brain volume loss correlated with
the daily dosage and total dosage of ACTH. Low dose
therapy was effective as the higher doses [101].
Favourable results especially in cryptogenic cases can
also obtained with even lower dosage of 0.1 I.U without
significant side effects [102]. With 2.5 IU/Kg daily a
77.4% of seizure free patients was obtained but 17%
patients encountered severe side effects such as major
infections which prompted a stop of the treatment
[103]. These results were confirmed by another study
with daily doses of 0.96 I.U/Kg for an average of 10 days
[104].
Summing up it can be said that when ACTH is used
as first line therapy low dosage for short period of treat-
ment seems to be today the best option.
Prednisolone has also been administered. In the Uni-
ted Kingdom Infantile Spasms study Prednisolone and
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Oral prednisolone was given at the dosage of 40 mg/
day, synthetic corticotropin depot 0.5 mg. on alternate
days The results of the two groups of patients were ces-
sation of spasms in 70% of patients treated with cortico-
tropin or prednisolone,54% in patients treated with
vigabatrin. Adverse events were reported in 55% of the
former group and in 54% of patients treated with viga-
batrin [105]. Thyrotropin releasing hormone (TRH) has
also been reported to be efficacious in IS Lennox-Gas-
taut syndrome and myoclonic seizures [106].
Antiepileptic drugs are also used for the treatment of
West syndrome. In a trial of combined treatment with
benzodiazepines on 24 cases, reduction or cessation of
spasms was obtained in 45.8% but the relapse rate was
18.2%. Psychomotor delay was present in 83.4% of cases
when treatment was completed. This treatment can be
utilized in cases of intolerance or adverse effect with
ACTH or vigabatrin [107].
Vigabatrin is used with advantage in treatment of IS
especially in cases associated to tuberous sclerosis com-
plex [108-110]. Doses are usually around 100 mg/Kg/
day with a gradual increase but maintained at the lowest
effective dosage. Superior doses seem not to be of bene-
fit. Vigabatrin is effective and well tolerated in IS. How-
ever there is no consensus on how long this treatment
should be maintained [111]. This treatment can be asso-
ciated with reduced visual function [112]. There is no
agreement whether this adverse event is related to
dosage, length of treatment or if the phenomenon is
reversible.
Zonisamide has been reported to be useful in West
syndrome. Dosage is variable from 4 to 22 mg/Kg/day.
It has been used mainly in Japan. Anorexia, gastrointest-
inal symptoms and leucopenia are reported as adverse
effects. White cell number must be monitored. Good
and excellent results are obtained either on spasms and/
or hypsarrhythmia [113-115].
Among the more recent antiepileptic drugs, positive
allosteric modulators for GABA receptors are effective
in controlling infantile spasms. Ganaxolone, a novel
neuroactive steroid, has demonstrated outstanding effi-
cacy but is not yet widely available [116,117]. Lamotri-
gine in low dosage is reported useful in symptomatic IS
[118].
There have been limited reports on the beneficial
effect of levetiracetam in cryptogenic IS [119-121].
Topiramate, a broad spectrum antiepileptic drug, has
been also used recently for treatment of West syndrome
in two large studies in China [122,123]. A significant
reduction in seizures was obtained. Side effects were
somnolence, sedation, lost of appetite and reduced dia-
phoresis. In the study it seems that in idiopathic patients
the results were better than in symptomatic cases
[124,125]. Topiramate was started with doses from 1
mg/kg/day and titrated to 20 mg/Kg/day. In all these
papers a distinction between results in symptomatic and
idiopathic cases is not indicated.
In our experience an add on treatment of vigabatrin
80-100 mg/Kg/day with topiramate 3-3.8 mg/Kg/day
obtained a complete clinical and EEG normalization
with neurodevelopmental normality which lasted 4 years
in 3 patients with idiopathic West syndrome, after gra-
dual withdrawal of both drugs. In one patient with West
syndrome associated with TSC there was only a partial
improvement [126].
Results with ketogenic diet are considered to be possi-
bly effective or ineffective as an alternative for the treat-
ment of IS [127,128].
The identification of focal or multifocal cortical
lesions with MRI and PET (positron emission tomogra-
phy) has led to the possibility of surgical approach for
some patients with intractable IS. When a single lesion
is present on MRI and/or PET and there is a correlation
with EEG localization, the results of surgical treatment
is reported to be quite favourable. [(11)c] Flumazenil
(FM2) which labels GABA (A) receptors and alpha [(11)
c] methyl-l-tryptophan (AMT) which is a capable of dif-
ferentiating between epileptogenic and non-epilepto-
genic lesions, can be particulary useful for this type of
evaluation [129,130].
When there are no localization, favourable results
have been reported in two patients with intractable IS
preceded by partial seizures with multiple subpial trans-
ections (MST) [131].
Iv immunoglobulins can be used as coadjuvant treat-
ment in cases which are difficult to control even in
symptomatic cases [132] and also for juvenile epileptic
spasms [133]. Prospective clinical trials however are
necessary in order to evaluate the usefulness of this
treatment.
High dose Vitamin B6 (pyridoxine) are reported to be
effective in West syndrome. The response to treatment
is rapid and seizures disappear within the first 2 weeks
of treatment. Gastrointestinal symptoms and liver dys-
functions are observed in 40-70% of subjects but they
resolve after reduction of dosage or discontinuation
[134].
Pyridoxal phosphate can be effective when there is no
response to pyridoxine [135,136].
Suggested Diagnostic Approach and Treatment
In order to give some practical cues we indicate in the
hereafter what we believe should be the approach when
dealing with a patient with IS.
With a careful clinical and developmental history and
examination, as well as the laboratory and instrumental
evaluation that are indicated in every single case, it is
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pathic IS. In particular the MRI must be of a very good
quality in order to disclose even minimal structural
abnormalities.
This workup must be performed before administering
any type of therapy
In idiopathic IS it is wise to begin the treatment with
the administration of 300 mg. of pyridoxine per os or i.
m. for 3 days. If there is no clinical or EEG response
Vigabatrin (VGB) and and topiramate (TPM) are pre-
ferred to ACTH, because side effects of these two drugs
are considered to be less dangerous then the those
caused by corticotropin treatment.
VGB is titrated to 100 mg./kg/day in 7 days period. If
after 15 days of treatment no results are obtained TPM
0.5 -1 mg./kg./day is prescribed and titrated to 5 mg./kg,
u pt o5m g . / k gi nam o n t hi fn e c e s s a r y .I ft h e r ei sn o
response to this treatment the use of Synachten depot is
considered with a dosage of 1-2 U./kg. day for a maxi-
mum of 20 days. A positive response must be obtained
within this period with disappearance of the spasms and
normalization of the EEG. These suggestions are sum-
marized in Fig. 2.
A clinical and EEG evaluation must be programmed
every month for the following six months. If the clinical
and EEG situation is normal at this date a gradual
decrease of the TPM dose in a three month period is
indicated. VGB thereafter can be also in the same time
period tapered off, thus minimizing the adverse effects
of this drug on the visual field. Of course the EEG must
always remain normal. Clinical and EEG evaluation
must then be programmed every 3 months for one year.
Symptomatic IS
It s not clear which therapy is recommended in sympto-
matic IS. When the etiology is TSC, VGB possibly asso-
ciated to TPM, should be considered. Frequently spasms
disappear to be substituted with partial seizures with or
without generalization. Zonisamide, lamotrigine, and
levetiracetam as well as other AEDs can also be used.
In other symptomatic IS it is necessary to evaluate the
aetiology and prescribe the therapy that is considered
more effective.
It is however recommended that therapy be planned
according to aetiology as in any other epileptic condi-
tion. Surgical treatment can be an option when focal
lesions are demonstrated.
Conclusions
IS is an age dependent epileptic encephalopathy asso-
ciated to different aetiologies which are today identifi-
able in the majority of cases.
Idiopathic IS is still an etiologically unresolved pro-
blem. Therapeutic response to corticotrophin and ster-
oids might suggest an immunological pathogenesis.
However, in apparently similar idiopathic cases com-
plete results can be obtained with AEDs which do not
have a demonstrated activity on the immune system.
In any case from a practical point of view in is impor-
tant to stress that a fast and long lasting normalization
can be obtained in idiopathic cases with early diagnosis
and proper therapy.
Appendix 1
Pathologies Associated with Infantile Spasms
Metabolic Disorders
Alexander disease
biotinidase deficiency
CDG deficient syndrome
d-bifunctional protein deficiency
d-glyceric aciduria
Hurler syndrome
hypoglycaemia
Leigh syndrome
Menkes disease
methylmalonic aciduria
mitochondrial diseases
phenylketonuria
propionic acidemia
Figure 2 Flow chart for treatment of infantile spasms.S e e
details in text.
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Page 7 of 10pyruvate dehydrogenase E1 alpha subunit deficiency
SCAD deficiency
vitamin B12 deficiency
Malformations and genetic disorders
cri du chat syndrome
Down’s syndrome
Familiar periventricular heterotopia
Gyration abnormalities
malformation of cortical development
microcephaly, lissencephaly and tetralogy of Fallot
Neurofibromatosis
polymicrogiria
sodium channel mutations
terminal 1p36 deletion
trisomy 4 p
Tuberous sclerosis complex
Dysmorphogenetic sindromes
Aicardi syndrome
Kabuki syndrome
Norrie disease
Schinzel-Giedion syndrome
Sotos syndrome
Williams syndrome with craniosynostosis
Other Conditions
Cerebral tuberculomas and neoplasms
Cytomegalovirus
DEND syndrome
Encephalomalacia
PEHO syndrome
Sturge-Weber syndrome
Familiar Cases
ARX mutations
CDKL5 mutations?
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